Shareholder Update – November 2015

Avatar

L.O.M. Medical International Inc. Issues Letter To Current Shareholders


L.O.M Medical International Inc. (“L.O.M” or the “Company”) is pleased to announce that it has completed and closed on $1.8 Mill on its previously announced Privileged Share offering through its wholly owned subsidiary L.O.M Laboratories Inc. The offering was made exclusively to existing shareholders on a pro rata basis from May 12, 2015 through June 12, 2015 at which time it was made available to all subscribers who qualified under Regulatory prospectus exemption rules. The Company anticipates it will complete the full $2 Mill offering by year end. Shareholders wishing to participate or requiring additional information on the Offering may contact us at by email
at Info@lommedical.com.

FINANCIAL UPDATE

L.O.M Audited Consolidated Financial Statements for the Year Ended May 31, 2015 will be distributed along with the shareholder meeting materials prior to the shareholder meeting. Details of which will be sent to shareholders in the near future.

In 2014 L.O.M made an offering to current and new shareholders in the form of a Convertible Debenture (the “Debenture”) which allowed those who wished to participate, the opportunity to purchase a debenture with terms including a 2 year maturity date and an interest rate of 8% per annum. The Company closed and issued $2,000,000 in convertible notes. The terms of the maturity date on $1,241,650 of the outstanding notes have been extended for a period of 12 months and the Company will be extending the same offer to the remaining note holders should they wish to do so. For those who decide not to extend the terms, the Company has secured the funds required to replace the notes not extended or converted on or before maturity.

CORPORATE LEGAL PROCEEDINGS

The Board of L.O.M Medical International and L.O.M Laboratories Inc. wish to advise its shareholders that a Statement of Claim was filed in the Court Queen’s Bench of Alberta on September 1, 2015 in the Judicial District of Calgary against the Directors, Officers, Advisory board members and several individual shareholders. The Plaintiffs listed are a small group of shareholders, which includes 1 debenture holder.

While the matters of the claim cannot be discussed within this update, L.O.M would like to note that it has retained the services of the Calgary Alberta office of Norton Rose Fulbright Canada LLP to represent the Defendants in this matter. It is the Defendants intention to vigorously defend and seek a full remedy against the claims made by the Plaintiff group.

UPDATE ON PROGRESS WITH DELOITTE CORPORATE FINANCE INC. OF CANADA

Deloitte continues to work with L.O.M providing the expertise and platform enabling us to find and negotiate with potential purchasers or joint venture partners as it pertains to the technology and the Company’s intellectual Property (the “IP”)

L.O.M expects to be able to provide shareholders with more detailed information about current discussions soon. Proceeds from the completed offering to shareholders is assisting in the patent and development costs as well as enabling L.O.M to continue to negotiate its IP with interested parties.

We point out the road ahead still requires considerable work, we will continue to focus our efforts to create value for our shareholders.

In closing the L.O.M board will continue to act accordingly in making what it feels are the appropriate changes to improve the Company going forward.

On Behalf of the Board,
Herbert Towning
President and CEO

Forward Looking Statements:  Certain statements in this release are forward-looking statements, which reflect the expectations of management. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations, assumptions or intentions regarding the future, including but not limited to that the company will be successful with ongoing negotiations. Such forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Particular risks applicable to this release include risks associated with ongoing and planned production programs.  No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. These forward-looking statements are made as of the date of this release and, except as required by law, the Company assumes no obligation to update these forward-looking statements, or to update the reasons why actual results differed from those projected in the forward-looking statements. Readers are cautioned not to rely on forward looking information as a result.